TEHEP-B

HIV-1 infection
Tenofovir is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults.
Tenofovir is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.
The choice of Tenofovir to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients.
Hepatitis B infection
Tenofovir is indicated for the treatment of chronic hepatitis B in adults with:
• compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.
• evidence of lamivudine-resistant hepatitis B virus.
• decompensated liver disease
Tenofovir are indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with:
• compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis

This is only the preview. Please check here for the full indication.

Anatomical Therapeutic Chemical: J
Dosage form: Film coated tablet
Packaging: 7's x 4
Therapeutic area: Active pharmaceutical ingredient: